Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502
Takashi Seto, Takeharu Yamanaka, Izumi Wasada, Nobuhiko Seki, Hiroaki Okamoto, Takashi Ogura, Masahiko Shibuya, Yuichi Takiguchi, Tetsu Shinkai, Noriyuki Masuda, Yukito Ichinose, Kenji Eguchi, Koshiro Watanabe
20100701
2010 Aug 1
Lung Cancer
Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502
Lung Cancer. 2010 Aug;69(2):213-217, Takashi Seto, Takeharu Yamanaka, Izumi Wasada, Nobuhiko Seki, Hiroaki Okamoto, Takashi Ogura, Masahiko Shibuya, Yuichi Takiguchi, Tetsu Shinkai, Noriyuki Masuda, Yukito Ichinose, Kenji Eguchi, Koshiro Watanabe
A phase I/II trial of TS-1 combined with gemcitabine was designed to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate the efficacy and toxicity in elderly patients with advanced non-small cell lung cancer (NSCLC). Patients older than 70 years of age received TS-1 orally b.i.d. on days 1–14 and gemcitabine intravenously on days 8 and 15 every 4 weeks. In phase I (n=22), each cohort received escalating doses of TS-1 (30–40mg/m2 b.i.d.) and gemcitabine (800–1000mg/m2);...
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
